Abstract
We investigated the modulating effect of L-leucovorin (LV) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells (C-1) in vitro and human colon carcinoma xenografts (Co-4) in nude mice. The modulating effect of LV on 5-FU reached an optimal concentration of 40–80 μg/ml in vitro which was detected by a colorimetric MTT assay. An optimal dose of 200 mg/kg was also observed in the nude mouse system. The modulating effect of LV increased according to the increment of thymidylate synthetase inhibition in vivo. Since the pharmacokinetic pattern of LV in the nude mice administered LV at 200 mg/kg was similar to that in patients treated with LV at a dose of 100 mg/m2, this clinical method of administration was thought to be adequate for modulating the antitumor activity of 5-FU against clinical colon carcinomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Comis RL, Carter SK (1974) Integration of chemotherapy into combined modality treatment of solid tumors. III Gastric cancer. Cancer Treat Rev 1:221–238
Ramming KP, Haskell CM (1985) Colorectal malignancies. In: Haskell CM (ed) Cancer treatment, 2nd edn. WB Saunders, Philadelphia, pp 295–334
Nadal JC, Groenigen CJ, Pinedo HM (1989) Schedule dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma. Invest New Drugs 7:163–172
Poon MA, O'Cornell MJ, Moertel CG (1989) Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407–1418
Bleyer WA (1989) New vistas for leucovorin in cancer chemotherapy. Cancer 63:995–1007
Kubota T, Nakada M, Tsuyuki K, Inada T, Asanuma F, Ishibiki K, Abe O (1986) Cell kinetics and chemosensitivity of human carcinomas serially transplanted into nude mice. Jpn J Cancer Res 77:502–507
Furukawa T, Kubota T, Suto A, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K, Kitajima M (1991) Clinical usefulness of chemosensitivity testing using the MTT assay. J Surg Oncol 48:188–193
Geran RI, Greenberg NH, Schumacher A, Abott BJ (1973) Protocols for screening chemical agents and natural products against animal tumors and other biological systems, 3rd edn. Cancer Chemother Rep 3:51–61
Yamamura K, Tanigawara Y (1983) Pharmacokinetics with personal Computer (in Japanese). Nankodo, Tokyo
Spears CP, Shahinian AM, Moran RG, Heidelberger C, Corbett TH (1982) In vivo kinetics of thymidylate synthetase inhibition on 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 42:450–456
Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L, Danenberg PV (1984) Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 44:4144–4180
Kubota T, Fujita S, Kodaira S, Yamamoto T, Josui K, Arisawa Y, Suto A, Ishibiki K, Abe O, Mabuchi K, Fuse M (1991) Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. Jpn J Cancer Res 82:476–482
Mabuchi M, Kaneko H, Kobari T (1986) Inhibition rate of thymidylate synthetase and correlation of FdUMP and dUMP in mouse tumor after administration of 5-fluorouracil (in Japanese). Jpn J Pharmacol 14:5683–5690
Glazer RI, Hartman KD (1979) The effect of 5-fluorouracil on the synthesis and methylation of molecular weight nuclear RNA in L1210 cells. Mol Pharmacol 17:245–249
Kufe DW, Major PP, Egan EM, Loh E (1981) 5-Fluoro-2-deoxyuridine incorporation into L1210 DNA. J Biol Chem 256:8885–8888
Danenberg PV, Heidelberger C, Mulkins M, Peterson AR (1981) The incorporation of 5-fluoro-2′-deoxyuridine into DNA of mammalian tumor cells. Biochem Biophys Res Commun 102:654–658
Schuetz JD, Wallace HJ, Diasio RB (1984) 5-Fluorouracil incorporation into DNA of cf-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res 44:1358–1363
Santi DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13:471–480
Houghton JA, Houghton PJ (1980) On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice. Cancer 45:1159–1167
Houghton JA, Maroda SJ, Phillips JO, Houghton PJ (1981) Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 41:144–149
Houghton JA, Schmidt C, Houghton PJ (1982) The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts. Eur J Cancer Clin Oncol 13:347–354
Evans RM, Laskin JD, Hakala MT (1981) Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41:3288–3295
Wright JE, Dreyfuss A, EI-Magharbel I (1989) Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 49:2592–2596
Houghton JA, Williams LG, Cheshire PJ (1990) Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma. Cancer Res 50:3940–3946
Martin DS, Stolfi R, Colofiore JR (1988) Failure of high-dose leucovorin to improve therapy with the maximally tolerated dose of 5-fluorouracil: A murine study with clinical relevance? J Natl Cancer Inst 80:496–501
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kase, S., Kubota, T., Watanabe, M. et al. The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo. Surg Today 23, 615–620 (1993). https://doi.org/10.1007/BF00311910
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00311910